Implementation of the 2019 lipid guidelines: where are we now?

Professor Alberico L. Catapano spoke about the European Atherosclerosis Society annual meeting, the novelties presented there, the ESC/EAS joint session discussing the new dyslipidemia guideline.

Detecting elevated lipoprotein(a) and addressing the ASCVD risks

Professor Florian Kronenberg presented the lipoprotein(a) consensus panel recommendations in the recent European Atherosclerosis Society 2022 Congress in Milan. He summarized for us our current knowledge about the role of lipoprotein(a) in cardiovascular diseases.

Who needs injectable therapies for cholesterol lowering or statins and ezetimibe are enough for CVD prevention?

Professor Carl Orringer was a co-chair of a recent symposium at the European Atherosclerosis Society 2022 session in Milan. The topic of the discussion was the potential role of the injectable therapies to prevent cardiovascular disease.

The difference between the genetic and pharmacological inhibition of PCSK9

Professor Giuseppe Danilo Norata discussed in the interview what is difference between PCSK9 genetic deficiency and PCSK9 pharmacological inhibition.

ESC/EAS joint session: What is new in secondary CV prevention?

Professor Ulrich Laufs talk about a very challenging topic, secondary cardiovascular prevention. At the European Atherosclerosis Society annual meeting he had a lecture, the ESC/EAS joint session about the societies prevention guideline, focusing on secondary prevention.

ESC/EAS joint session 2022: Advances in CV risk estimation with focus on dyslipidemia

Professor Ian Graham shared us the advances of the cardiovascular risk collaboration he spoke about at the ESC/EAS joint session at the EAS 2022 Congress. He is Professor of Cardiovascular Medicine at the Trinity College in Dublin, Ireland. He is the member of the ESC. He has been involved in the preparation of the prevention guidelines from the 1990’s. He became also the chair of the ESC CV risk collaboration.